Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Simvastatin

Simvastatin, a diminutive molecular entity, functions as an HMG-CoA reductase enzyme inhibitor, which is accountable for the synthesis of cholesterol in the hepatic tissue. Classified as HMG-CoA reductase inhibitors or statins, it treats sundry ailments that result from elevated cholesterol levels. Simvastatin's active indications encompass heterozygous familial hypercholesterolemia, hyperlipoproteinemia Type V, stroke, hyperlipidemias, and hyperlipoproteinemia Type II. Merck Sharp & Dohme Corp. initially synthesized simvastatin, and it received the first nod for clinical use in 1988. In spite of its prevalent administration, simvastatin may elicit an array of side effects, for example, myalgia and hepatotoxicity, and patients should seek counsel from their medical practitioners before initiating its intake. Click on the image below to begin the exploration journey of Simvastatin through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!